Literature DB >> 17343309

Synovial macrophages as a biomarker of response to therapeutic intervention in rheumatoid arthritis: standardization and consistency across centers.

Barry Bresnihan1, Danielle M Gerlag, Terence Rooney, Tom J M Smeets, Carla A Wijbrandts, David Boyle, Oliver Fitzgerald, Bruce W Kirkham, Iain B McInnes, Malcolm Smith, Ann-Kristin Ulfgren, Douglas J Veale, Paul P Tak.   

Abstract

Successive studies from one academic center (Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands) have consistently suggested that synovial tissue expression of sublining macrophages may be a biomarker of clinical response to therapeutic intervention in rheumatoid arthritis (RA) clinical trials. A proof-of-concept, randomized clinical trial was completed at a second academic center (St. Vincent's University Hospital, Dublin, Ireland), and the relationship between the change in disease activity and the change in sublining macrophages in distinct treatment cohorts was determined. The preliminary findings were not conclusive, but appeared to support a role for sublining CD68+ macrophages as a biomarker of clinical response to therapeutic intervention in cohorts of patients with RA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17343309

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  33 in total

Review 1.  Liquid biopsies to guide therapeutic decisions in rheumatoid arthritis.

Authors:  Roxana Coras; Rekha Narasimhan; Monica Guma
Journal:  Transl Res       Date:  2018-07-19       Impact factor: 7.012

2.  Monocyte/Macrophage Abnormalities Specific to Rheumatoid Arthritis Are Linked to miR-155 and Are Differentially Modulated by Different TNF Inhibitors.

Authors:  Audrey Paoletti; Julien Rohmer; Bineta Ly; Juliette Pascaud; Elodie Rivière; Raphaele Seror; Benoit Le Goff; Gaetane Nocturne; Xavier Mariette
Journal:  J Immunol       Date:  2019-09-04       Impact factor: 5.422

Review 3.  Synovial cellular and molecular markers in rheumatoid arthritis.

Authors:  M Asif Amin; David A Fox; Jeffrey H Ruth
Journal:  Semin Immunopathol       Date:  2017-05-11       Impact factor: 9.623

4.  Neoangiogenesis contributes to the development of hemophilic synovitis.

Authors:  Suchitra S Acharya; Rosandra N Kaplan; Dan Macdonald; Oluwa T Fabiyi; Donna DiMichele; David Lyden
Journal:  Blood       Date:  2010-12-16       Impact factor: 22.113

5.  Cyclin-dependent kinase inhibitor p21, via its C-terminal domain, is essential for resolution of murine inflammatory arthritis.

Authors:  Melissa Mavers; Carla M Cuda; Alexander V Misharin; Angelica K Gierut; Hemant Agrawal; Evan Weber; Deborah Veis Novack; G Kenneth Haines; Dimitrios Balomenos; Harris Perlman
Journal:  Arthritis Rheum       Date:  2012-01

Review 6.  The role of biomarkers in the management of patients with rheumatoid arthritis.

Authors:  Jackie Nam; Edith Villeneuve; Paul Emery
Journal:  Curr Rheumatol Rep       Date:  2009-10       Impact factor: 4.592

7.  Computer-assisted validation of the synovitis score.

Authors:  Lars Morawietz; Frank Schaeper; Joerg H Schroeder; Tserenchunt Gansukh; Nachin Baasanjav; Manfred G Krukemeyer; Thorsten Gehrke; Veit Krenn
Journal:  Virchows Arch       Date:  2008-02-19       Impact factor: 4.064

8.  Synovial tissue hypoxia and inflammation in vivo.

Authors:  C T Ng; M Biniecka; A Kennedy; J McCormick; O Fitzgerald; B Bresnihan; D Buggy; C T Taylor; J O'Sullivan; U Fearon; D J Veale
Journal:  Ann Rheum Dis       Date:  2010-05-03       Impact factor: 19.103

Review 9.  The inflammatory role of phagocyte apoptotic pathways in rheumatic diseases.

Authors:  Carla M Cuda; Richard M Pope; Harris Perlman
Journal:  Nat Rev Rheumatol       Date:  2016-08-23       Impact factor: 20.543

10.  A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue.

Authors:  A W R van Kuijk; D M Gerlag; K Vos; G Wolbink; M de Groot; M A de Rie; A H Zwinderman; B A C Dijkmans; P P Tak
Journal:  Ann Rheum Dis       Date:  2008-07-22       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.